Sun Pharma

Sun Pharmaceutical Industries on Wednesday said it has partnered with Royal Challengers Bengaluru as principal sponsor and health partner for a three-year period starting with the 2026 season. The partnership marks the Mumbai-based drug major's first-ever foray into cricket sponsorship, signaling a significant milestone in its corporate brand journey, the company said in a statement. "RCB and Sun Pharma are both leaders in their respective domains, and this collaboration reflects our shared values of consistency, passion and innovation," Sun Pharma Managing Director Kirti Ganorkar said. Through this partnership, Sun Pharma aims to strengthen its corporate brand connect with people across India by bringing them closer to the company they rely on every day medicines, he added. "Sun Pharma joining us as our Principal Sponsor strengthens this commitment, bringing together two brands focused on impact and innovation," Royal Challengers Bengaluru (RCB) COO Rajesh Menon said.

Strong Q3 performance and a steady pipeline of new launches are expected to support Sun Pharma's growth outlook, with brokerages upgrading the stock

Sun Pharmaceutical Industries expects pressure on its US generics business to ease as compliance improves, while focusing growth efforts on innovation-led therapies

Sun Pharma reported a 16 per cent year-on-year (Y-o-Y) growth in its consolidated profit after tax (PAT) at ₹3,369 crore for Q3FY26

Stocks to Watch today, February 1, 2026: From Glenmark Pharma to Ola Electric, here are few shares that will remain in focus

US generics remain under pressure while API revenues decline during the quarter

Q3FY26 company results: Firms including Bharat Dynamics, ZF Steering Gear India, R R Kabel, Finolex Industries and Reliance Infrastructure are also to release their October-December earnings today

A technical scan on Nifty 500 stocks reveals that 6 shares were trading in overbought territory based on the RSI parameter, while 66 languished in the oversold zone a day ahead of the Union Budget.

Sun Pharma's net profit is expected to come at ₹3,040 crore, marking a decline of 5.6 per cent Y-o-Y, as against ₹3,220 crore in the year-ago period

In 2024, the ​USFDA issued a warning letter to Sun Pharma alleging 'significant violations' of 'current good manufacturing practice' ‍regulations for pharma made at the same production site in India

Drugmakers Sun Pharma and Cipla are recalling products in the US due to manufacturing related issues, according to the US Food and Drug Administration. As per its latest Enforcement Report, the US-based arm of Mumbai-based Sun Pharma is recalling over 26,000 bottles of a generic medication to treat dandruff and skin conditions with inflammation and itching. The Princeton (New Jersey)-based Sun Pharmaceutical Industries Inc is recalling 24,624 bottles of Fluocinolone Acetonide Solution Topical Solution for "Failed Impurities/Degradation Specifications", the US health regulator said. The company initiated the Class III nationwide (US) recall on December 30, 2025. The US Food and Drug Administration (USFDA) noted that the company is also recalling certain batches of a medication to treat acne vulgaris. Sun Pharmaceutical Industries Inc initiated the Class III recall of Clindamycin Phosphate USP on November 26, 2025 due to "Failed Impurities/Degradation: Out of Specification results f

India has entered the first phase of generic semaglutide approvals, with CDSCO clearing multiple formulations for obesity and diabetes, paving the way for lower-cost GLP-1 therapies

Sun Pharma said it will launch generic semaglutide in India after the patent expiry in March 2026, becoming the second domestic drugmaker to secure regulatory approval for the blockbuster drug

Sun Pharmaceutical said reports of a $10 billion acquisition of US-based Organon are speculative, adding there is no material information requiring disclosure to exchanges

Strong domestic demand is set to lift pharma revenues by up to 11% in Q3FY26, though pressure from generic Revlimid in the US may limit profit growth

In the past two trading days, the Nifty Pharma index has rallied 3.3 per cent, as compared to 0.41 per cent decline in the Nifty 50.

Improving access to new age medicines for obesity and diabetes over the next few years would be a key enabler for the growth of the domestic pharmaceutical industry, according to Sun Pharma Managing Director Kirti Ganorkar. Glucagon-like peptide-1 (GLP-1) receptor agonists are drugs that treat type 2 diabetes, high blood sugar, and obesity by regulating insulin production. India, known for its generic drug industry, is rapidly transforming into a major hub for the global weight management industry, amid rapid increase in obesity-led disease burden. "Improving access to GLP-1 treatments in the coming years will be a key driver for the Indian pharmaceutical industry, helping address the growing burden of lifestyle diseases such as obesity and diabetes," Ganorkar told PTI. Combined with AI-enabled digital tools for early disease detection and monitoring, and personalised medicine choices, the industry will continue to drive innovation that supports accessibility, affordability, and ..

The USFDA said the affected batch of Taro shampoos failed to meet impurity or degradation specifications

Sun Pharma's Baska plant in Gujarat receives OAI status from the US FDA after inspection, adding near-term regulatory uncertainty but not impacting current US supplies

The USFDA conducted an inspection at the company's Baska facility from 8 September 2025 to 19 September 2025 and has subsequently classified the inspection outcome as Official Action Indicated (OAI)